for *in situ* hybridisation a (16S) ribosomal RNA molecule. In a particular embodiment of the invention said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTTCGAATG (SEQ ID NO:1) or GTAGCCCTACTCGTAAGG (SEQ ID NO:2) or GAGCAAAGGTATTAACTTTACTCCC (SEQ ID NO:3) or GTTAGCCGTCCCTTTCTGG (SEQ ID NO:4) or TTATCCCCCTCTGATGGG (SEQ ID NO:5) or AGAGAAGCAAGCTTCTCGTCCG (SEQ ID NO:6) or GCCACTCCTCTTTTTCCGG (SEQ ID NO:7) or GCTAATGCAGCGCGGATCC (SEQ ID NO:8) or CCGAAGGGGAAGGCTCTA (SEQ ID NO:9) or AGAGAAGCAAGCTTCTCGTCCGTT (SEQ ID NO:10), each selected in relation to a method as provided by the invention or in relation to congruent antibiotic sensitivity of a bacterium recognised by said probe.

Please delete the last paragraph of page 9 and replace it with the following substitute paragraph.

—Such a positive or negative control probe as provided by the invention is given in the experimental part, in general said positive control probe comprises no more than five mismatches with a probe with the sequence GCTGCCTCCCGTAGGAGT (SEQ ID NO:11) and/or said negative control probe comprises no more than five mismatches with a probe with the sequence ACTCCTACGGGAGGCAGC (SEQ ID NO:12).

Please delete the second paragraph on page 10 and replace it with the following substitute paragraph.

five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTTCGAATG (SEQ ID NO:1) or GAGCAAAGGTATTAACTTTACTCCC (SEQ ID NO:3) (i.e. reactive with bacteria for which amoxycillin treatment is most likely effective) or GTAGCCCTACTCGTAAGG (SEQ ID NO:2) (cephalosporin treatment) or GTTAGCCGTCCCTTTCTGG (SEQ ID NO:4) (piperacillin and/or aminoglycoside) or TTATCCCCCTCTGATGGG (SEQ ID NO:5) or GCCACTCCTTTTTCCGG (SEQ ID NO:7) (amoxycillin) or GCTAATGCAGCGCGGATCC (SEQ ID NO:8) or CCGAAGGGGAAGGCTCTA (SEQ ID NO:9) (vancomycin) or AGAGAAGCAAGCTTCTCGTCCGTT (SEQ ID NO:10) or AGAGAAGCAAGCTTCTCGTCCG (SEQ ID NO:6) (flucloxacilin).—



Please delete the table near the top of page 16 and insert in its place the following substitute table.

ID	Sequence (5'-3')	Region ²	Specificity ³	
A	GCTGCCTCCCGTAGGAGT	V2	Bacterial Kingdom	
	(SEQ ID NO:11)			
В	ACTCCTACGGGAGGCAG	n.d.	no matches	
	C (SEQ ID NO:12)			
C	GCCTGCCAGTTTCGAATG	V2	Salmonella spp., Klebsiella	
	(SEQ ID NO:1)		spp., Enterobacter spp.	
D	GTAGCCCTACTCGTAAG	V7	K. oxytoca, S. marcescens,	
	G (SEQ ID NO:2)		Enterobacter spp.,	
			Proteus spp.	
Е	GAGCAAAGGTATTAACT	V3	E. coli	
	TTACTCCC (SEQ ID NO:3)			
F	TTATCCCCCTCTGATGGG	V2	E. faecalis	
	(SEQ ID NO:5)			
G	GCTAATGCAGCGCGGAT	V2	S. aureus,	
	CC (SEQ ID NO:8)		S. haemolyticus	
Н	CCGAAGGGAAGGCTCT	V6	S. aureus,	
	A (SEQ ID NO:9)		S. saprophyticus	
I	AGAGAAGCAAGCTTCTC	V1	Streptococcus spp.	
	GTCCG (SEQ ID NO:6)			
J	GTTAGCCGTCCCTTTCTG	V3	P. aeruginosa	
	G (SEQ ID NO:4)			
K	AGAGAAGCAAGCTTCTC	V2	S. aureus	
	GTCCGTT (SEQ ID NO:10)			
L	GCCACTCCTCTTTTCCG	??	Enterococcus faecium	
	G (SEQ ID NO:7)			

Please delete Table 3 near the top of page 24 and substitute the following table in its place.

Probe*	Sequence (5'→3')	Target(s)	Preferred antibiotic**
EUB	GCTGCCTCCCGTAGG	Bacterial Kingdom	n.a.***
	AGT (SEQ ID NO:11)		
non-EUB	ACTCCTACGGGAGGC	negative control	n.a.
	AGC (SEQ ID NO:12)		
STREP	GTTAGCCGTCCCTTT	Streptococcus spp.	Penicillin G
	CTGG (SEQ ID NO:4)		
EFAEC	TTATCCCCCTCTGAT	Enterococcus faecalis	Amoxycillin
	GGG (SEQ ID NO:5)		
EFAEM	GCCACTCCTCTTTTT	Enterococcus	Vancomycin
	CCGG (SEQ ID NO:7)	faecium	
STAUR	AGAGAAGCAAGCTT	Staphylococcus	Flucloxacillin
	CTCGTCCG	aureus	
	(SEQ ID NO:6)		
CNS	CGACGGCTAGCTCCA	Coagulase-negative	Vancomycin
	AATGGTTACT	Staphylococci	
	(SEQ ID NO:13)		
ECOLI	GCAAAGGTATTAACT	Escherichia coli	Amoxycilin
	TTACTCCC		
	(SEQ ID NO:14)		
PSEUDA	GGACGTTATCCCCCA	Pseudomonas	Piperacillin+
ER	CTAT (SEQ ID NO:15)	aeruginosa	aminoglycoside
ENTBAC	CATGAATCACAAAGT	Enterobacterium spp.	2 nd generation
	GGTAAGCGCC		cephalosporin
	(SEQ ID NO:16)		

IN THE CLAIMS

Please amend the following claims to read as follows.

more than tive, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTTCGAATG (SEQ ID NO:1) or